A double-blind,randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy |
| |
Authors: | Fuentes Virginia Luis Corcoran Brendan French Anne Schober Karsten E Kleemann Rainer Justus Claus |
| |
Institution: | Department of Veterinary Clinical Studies, Royal Dick School of Veterinary Studies, Summerhall, Edinburgh, UK. luis-fuentes.1@osu.edu |
| |
Abstract: | A double-blind, randomized, placebo-controlled study was conducted to examine the effect on heart failure class and survival of pimobendan, an oral calcium-sensitizing inodilator, in dogs with dilated cardiomyopathy (DCM). Pimobendan (0.3-0.6 mg/kg body weight/d) or placebo was administered to English Cocker Spaniels (CSs; n = 10) and Doberman Pinschers (DPs: n = 10) that had DCM in addition to background therapy of furosemide, enalapril, and digoxin. Addition of pimobendan to standard triple therapy was associated with a significant improvement in heart failure class, regardless of breed (P < .02, Mann-Whitney rank sum test). Overall, 8 of 10 animals in the pimobendan-treated group, and 1 of 10 animals in the placebo group improved their heart failure status by at least I modified New York Heart Association functional class after initial stabilization (P = .005, Fisher's exact test). Pimobendan had no significant effect on survival in the CSs (P = 0.77, log-rank test), but DPs treated with pimobendan had significantly longer survival times compared with placebo (P < .02, log-rank test), with a median survival time of 329 days in the pimobendan group compared with 50 days in the placebo group, and a hazard ratio of 3.4 (95% confidence interval 1.4-39.8). Pimobendan resulted in significant improvement in heart failure class when added to standard therapy in this group of dogs with DCM, and may have contributed to improved survival in DPs. |
| |
Keywords: | Calcium-sensitizing agent Congestive cardiac failure Doberman Pinscher English Cocker Spaniel Heart Inodilator |
本文献已被 PubMed 等数据库收录! |
|